A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Japanese Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2017
At a glance
- Drugs AZD 4547 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jan 2017 Results published in the Investigational New Drugs:The Journal of New Anticancer Agents.
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.